Trials / Unknown
UnknownNCT05729360
Study of Monoclonal Antibodies for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus
"An Open Safety Study and Description of the Parameters of the Therapeutic Efficacy of the Drug for Early Etiotropic Therapy for Coronavirus Infection Caused by the SARS-CoV-2 Virus, With a Single Application in Patients With Confirmed COVID-19 Diagnosis"
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Open prospective non-comparative study of safety and tolerability of the drug (GamCoviMab) with the description of the parameters of the therapeutic efficacy in patients with confirmed COVID-19 diagnosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GamCoviMab | A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization). |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2023-02-15
- Last updated
- 2023-02-15
Source: ClinicalTrials.gov record NCT05729360. Inclusion in this directory is not an endorsement.